Compare DKL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DKL | GPCR |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2012 | 2023 |
| Metric | DKL | GPCR |
|---|---|---|
| Price | $55.38 | $47.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $53.67 | ★ $103.17 |
| AVG Volume (30 Days) | 106.0K | ★ 808.9K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.84 | $15.80 |
| 52 Week High | $56.83 | $94.90 |
| Indicator | DKL | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 45.84 |
| Support Level | $49.36 | $42.72 |
| Resistance Level | $55.89 | $57.15 |
| Average True Range (ATR) | 1.13 | 2.95 |
| MACD | 0.26 | -1.05 |
| Stochastic Oscillator | 74.28 | 17.92 |
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.